7/7/2014 8:27:58 AM
OXFORD, UK and MARLBOROUGH, MA, July. 07, 2014 (GLOBE NEWSWIRE) – Oxford Immunotec
Global PLC (NASDAQ: OXFD), a global, commercial-stage diagnostics company committed to improving
patient care by providing advanced, innovative tests in the field of immunology, today announced that
Louis O’Dea, MB, BCh, BAO, has joined the company as Chief Medical Officer. Dr. O’Dea brings to
Oxford Immunotec more than 20 years of worldwide pharmaceutical, medical device, and biotechnology
industry management experience. Dr. O’Dea will support the continued growth of our current T-SPOT.TB
business and the development of new products through management of our medical education and
clinical trial programs. Prior to joining Oxford Immunotec, Dr. O’Dea served as the Chief Medical Officer
and Head of Regulatory Affairs at Moderna Therapeutics. Prior to Moderna, he was Chief Medical Officer
of Radius Health, Inc. and Head of Clinical Development for the Metabolic and Reproductive Health unit
of Serono, a division of Merck.
”Oxford Immunotec is a leader in the world of immunology-based diagnostics, proven by the global
success of the T-SPOT.TB test and a robust pipeline of products based on its core T-SPOT technology
platform,” said Dr. O’Dea. “I look forward to contributing to the Company’s continued success as it grows
and expands into new markets.”
“Dr. O’Dea is accomplished in successfully managing both pharmaceuticals and devices through clinical
trials, regulatory approval and commercialization in the US, Europe and Japan. We are extremely
fortunate to have him join our team,” said CEO, Dr. Peter Wrighton-Smith. “The breadth and depth of
Louis’s clinical development experience will be instrumental to Oxford Immunotec’s efforts to launch new
products well-supported with clinical data and well-suited to the needs of the market.”
Dr. O’Dea is a board-certified physician in internal medicine and endocrinology in the United States and
Canada. He received his MB, BCh, and BAO degrees from University College in Dublin, Ireland, followed
by postgraduate training in Internal Medicine and Endocrinology at McGill University, and a research and
clinical fellowship in reproductive endocrinology at Massachusetts General Hospital.
About Oxford Immunotec Global PLC
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company committed to
improving patient care by providing advanced, innovative tests in the field of immunology. The proprietary
T-SPOT® technology platform measures the responses of specific immune cells, known as T cells, to
inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. T
cells are a central component of the human body’s immune system, and are implicated in the control and
progression of many medical conditions, including certain types of infectious diseases, cancers and
autoimmune diseases. The Company’s initial product developed using the T-SPOT technology platform is
the T-SPOT.TB test, which is used to test for latent tuberculosis infection. The T-SPOT.TB test has been
approved for sale in over 50 countries, including the United States, where it has received pre-market
approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as
Japan and China. The Company is headquartered near Oxford, UK and in Marlborough, MA.
Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
This release contains forward-looking statements, including statements regarding future success of the
company. These forward-looking statements are subject to risks and uncertainties that could cause actual
results to differ materially. Forward-looking statements are based on current expectations and
assumptions and currently available data and are neither predictions nor guarantees of future events or
performance. You should not place undue reliance on forward-looking statements, which speak only as of
the date of this presentation. We do not undertake to update or revise any forward-looking statements
after they are made, whether as a result of new information, future events, or otherwise, except as
required by applicable law.
For Media Inquiries:
Tel: +44 1235 442796
For Investor Inquiries:
Chief Financial Officer,
Tel: +1 (508) 481-4648
Tel: +1 (443) 213-0500
Help employers find you! Check out all the jobs and post your resume.
comments powered by